The company completed the sale of its Critical Care product group for $4.2 billion, a strategic move to focus on implantable medical innovations for structural heart disease. This divestiture is expected to allow for expanded opportunities in TAVR, TMTT, and Surgical patients.

The company acquired all outstanding shares of Endotronix, Inc., a developer of implantable sensors for heart failure management, for $798.8 million. This acquisition aims to expand Edwards' structural heart portfolio into a new therapeutic area.

R&D expenses increased for the three and nine months ended September 30, 2024, reflecting the company's continued investments in aortic transcatheter valve innovations, including increased clinical trial activity.

The company recorded restructuring expenses of $32.9 million in September 2024 related to a global workforce realignment impacting approximately 360 employees. This indicates management's efforts to optimize operational efficiency.

The company continues an internal review and investigation into potential FCPA violations in Japan and other markets. While the SEC has stated it is not recommending enforcement action, the matter remains under review.

The company is contesting a notice of deficiency from the IRS for 2015-2017 tax years, related to transfer pricing, and has made a $305 million deposit to mitigate interest on potential tax liabilities, demonstrating a proactive approach to managing tax disputes.

The company is involved in ongoing intellectual property litigation, including a lawsuit filed by Aortic Innovations LLC, which could impact the company's financial results if not resolved favorably.

The company faces uncertainty related to transfer pricing matters, ongoing IRS audits, and other tax positions, which could result in material tax liabilities and impact the company's financial statements.

The company is subject to various pending or threatened lawsuits, and the resolution of these lawsuits could have a material adverse impact on the company's financial results for a given period.

The medical technology industry is highly competitive and continues to evolve, requiring the company to focus on innovation and value creation to maintain its market position.

The company is dedicated to generating robust clinical, economic, and quality-of-life evidence to encourage the adoption of its innovative medical therapies, which is a key factor in maintaining a competitive edge.

The company experienced some regional sales pressure and a reduction in procedures with certain hospital centers in the United States, indicating potential competitive challenges or market dynamics.

Foreign currency exchange rate fluctuations decreased expenses by $2.9 million and $8.6 million for the three and nine months ended September 30, 2024, respectively, primarily due to the strengthening of the United States dollar against the Japanese yen.

Selling, general, and administrative expenses increased due to higher field-based personnel-related costs in support of the company's growth strategy initiatives, indicating a focus on sales and market expansion.

The company continues to manage its global supply chain to support its manufacturing operations, indicating a focus on maintaining operational efficiency.

The company's R&D expenses increased, reflecting ongoing investments in transcatheter valve innovations, including increased clinical trial activity.

The company is committed to developing new technologies and innovations to transform care for those impacted by structural heart disease, demonstrating a focus on technological advancement.

The company is pursuing new investments in interventional heart failure technologies, showing a commitment to expanding its product portfolio and addressing a wider range of patient needs.

The company repurchased 15.0 million shares for $1.2 billion during the nine months ended September 30, 2024, and has $1.4 billion remaining under its share repurchase authorization, indicating a commitment to returning value to shareholders.

The company completed acquisitions for a total of $1.5 billion, including Endotronix and JC Medical, and has potential payments of $670 million upon achievement of certain milestones, demonstrating a focus on strategic growth through acquisitions.

The company's debt financing remains stable with $600 million of 4.3% fixed-rate unsecured senior notes due in 2028 and a $750 million revolving credit facility, indicating a balanced approach to capital structure.

The filing does not explicitly discuss any specific environmental, social, or governance initiatives, indicating a potential area for further disclosure or development.

The company is subject to various environmental laws and regulations, and management believes that compliance will not have a material impact on financial results, indicating a focus on regulatory compliance.

The filing does not explicitly discuss any specific governance practices, indicating a potential area for further disclosure or development.

The company's net sales and expenses are impacted by foreign currency exchange rate fluctuations, particularly the weakening of the Japanese yen against the United States dollar, indicating sensitivity to global economic conditions.

The company is subject to ongoing regulatory scrutiny, including tax audits and investigations, and potential changes in tax laws, which could impact its financial results.

The company is evaluating the impact of new accounting standards, including those related to income statement presentation and segment reporting, which could affect future financial reporting.